GeneDx Holdings Corp.
Rank #49HypergrowthWGSWW · Nasdaq
GeneDx Holdings Corp. (WGSWW) — Rank #49 by gross profitability (GP/assets 0.62) · ROE -8.6% · Piotroski F-Score 6 / 9.
As-of 2026-09-15 · CIK 0001818331 · all metrics point-in-time as of the filing date.
About
GeneDx Holdings Corp., a genomics company, provides genetic testing services.
Show moreShow less
The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp.
was founded in 2000 and is headquartered in Stamford, Connecticut.
- State
- DE
- Filer Category
- Large accelerated filer
- Fiscal Year End
- December 31
- Website
- genedx.com
Financials
Each fiscal year is read as-of that year’s own 10-K filing, so nothing restated after the fact leaks backwards. Line items this filer never tagged are omitted. Hover or tap a badge for the diagnostic behind it.
| Fiscal year end | 2025-12-31filed 2026-02-23 | 2024-12-31filed 2025-02-20 | 2023-12-31filed 2024-02-23 | 2022-12-31filed 2023-03-16 |
|---|---|---|---|---|
| Revenue | 427.5 | 305.5 | 202.6 | 234.7 |
| Revenue growth (YoY) | 40.0% | 50.8% | -13.7% | 10.6% |
| Cost of revenue | 129.4 | 111.1 | 112.6 | 261.4 |
| Gross profit | 298.2 | 194.4 | 90.0 | (26.8) |
| Gross margin | 69.7% | 63.6% | 44.4% | -11.4% |
| Research & development | 72.0 | 45.7 | 58.3 | 86.2 |
| Operating income | (13.1) | (23.2) | (180.6) | (667.7) |
| Operating margin | -3.1% | -7.6% | -89.2% | -284.5% |
| Interest income | — | — | — | 2.5 |
| Interest expense | — | — | — | 3.2 |
| Pre-tax income | (21.1) | (52.6) | (176.7) | (598.0) |
| Income tax expense | (0.1) | (0.3) | (0.9) | (49.1) |
| Net income | (21.0) | (52.3) | (175.8) | (549.0) |
| Net margin | -4.9% | -17.1% | -86.8% | -233.9% |
| EPS (basic) | -$0.73 | -$1.94 | -$7.23 | -$1.63 |
| EPS (diluted) | -$0.73 | -$1.94 | -$7.23 | -$1.63 |
Figures are as originally filed with the SEC (point-in-time), not restated, so they can differ slightly from sites that show later-restated numbers. Why point-in-time?